Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High - Here's Why

Key Points

• Charles River Laboratories’ stock reached a new 52-week high of $359.89 during Tuesday trading, with a market capitalization of approximately $17.03 billion.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $302.33; recent firms raised targets as high as $334.
• The company exceeded quarterly earnings expectations, reporting $3.02 in adjusted EPS versus $2.77 expected and $1.0 billion in revenue, while revenue declined 2.7% year over year. Institutional investors own 98.91% of the stock, and insiders sold roughly $35.2 million in shares over the past three months.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $359.89 and last traded at $354.94, with a volume of 77,128 shares changing hands. The stock had previously closed at $357.27.

Analyst Ratings Changes

A number of brokerages have weighed in on CRL. Deutsche Bank Aktiengesellschaft increased their target price on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, September 25th. Mizuho upped their price target on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the company a "neutral" rating in a research note on Friday, September 25th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Finally, Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $302.33.

Charles River Laboratories International Stock Performance

The business's fifty day moving average price is $295.70 and its 200-day moving average price is $219.36. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market capitalization of $17.03 billion, a PE ratio of -73.63, a P/E/G ratio of 3.23 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Insider Activity

In related news, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares of the company's stock, valued at approximately $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares of the company's stock, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 118,169 shares of company stock worth $35,191,216. Company insiders own 1.30% of the company's stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Amundi boosted its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock valued at $59,044,000 after purchasing an additional 142,716 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Charles River Laboratories International by 2,268.2% in the third quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock valued at $32,977,000 after purchasing an additional 107,061 shares in the last quarter. Finally, Ranger Investment Management L.P. bought a new stake in Charles River Laboratories International during the first quarter valued at approximately $12,198,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.